Bristol Releases More Phase III Data For First In Class Dapagliflozin, Says Filing Is On Track
This article was originally published in The Pink Sheet Daily
Executive Summary
Troublesome genital infection side effects pop up yet again, but tended to be mild to moderate. Optimal dose still not decided.